Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity
Sponsor: Novo Nordisk A/S
Summary
This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001 or a placebo; which treatment each participant receives will be decided by chance.
Official title: A First Human Dose Study Investigating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single and Multiple Ascending Doses of NNC6989-0001 in Healthy Participants With Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2026-02-24
Completion Date
2027-01-21
Last Updated
2026-02-27
Healthy Volunteers
Yes
Conditions
Interventions
NNC6989-0001 A
Participants assigned to the active intervention receive NNC6989-0001 A
Placebo (NNC6989-0001 A)
Participants assigned to the placebo, receive placebo matched in appearance to the active drug.
Locations (1)
ICON Early Phase Services, LLC
Lenexa, Kansas, United States